XIENCE V Drug Eluting Stent From Abbott Outperforms Market-Leading Stent In Reducing Major Adverse Cardiac Events At Two Years
May 21st, 2008 by 
admin Long-term accumulation presented for the prototypal instance from the SPIRIT threesome trial, Abbott’s U.S. important effort studying the XIENCE™ V Everolimus Eluting Coronary Stent System, demonstrated that XIENCE V continues to have clinically crack benefits for patients compared to the TAXUS® paclitaxel-eluting thrombosis stent system.
Posted in Cardiology | 